Inventor · disambiguated record
John F. Traverse
Also filed as: TRAVERSE JOHN · TRAVERSE JOHN F · TRAVERSE JOHN FITZGERALD
28 granted patents·8 pending applications·68 citations·filing 2007–2025
95Inventor score
Files withCELGENE CORP25SIGNAL PHARM LLC3CELGENE CAR LLC2CELGENE QUANTICEL RES INC2BRISTOL MYERS SQUIBB CO1
Top patents by PatentIndex Score
36 records- 0195US9221788B2Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2013·Granted Dec 29, 2015·21 cites·77 claims
- 0293US10894796B2MK2 inhibitors, synthesis thereof, and intermediates theretoCELGENE CAR LLC·Filed 2018·Granted Jan 19, 2021·8 cites·19 claims
- 0392US10646503B2Isotopologues of 5-azacytidineCELGENE CORP·Filed 2019·Granted May 12, 2020·2 cites·1 claims
- 0491US12343346B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2024·Granted Jul 1, 2025·0 cites·7 claims
- 0591US9629849B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2015·Granted Apr 25, 2017·7 cites·41 claims
- 0689US9309220B2Processes for the preparation of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereofCELGENE CORP·Filed 2013·Granted Apr 12, 2016·14 cites·34 claims
- 0788US10463683B2Isotopologues of 5-azacytidineCELGENE CORP·Filed 2019·Granted Nov 5, 2019·3 cites·1 claims
- 0887US10220050B2Isotopologues of 5-azacytidineCELGENE CORP·Filed 2017·Granted Mar 5, 2019·3 cites·1 claims
- 0987US2025281501A1Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2025·Application pending·0 cites
- 1086US12435028B2Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoateCELGENE CORP·Filed 2024·Granted Oct 7, 2025·0 cites·6 claims
- 1185US11655257B2MK2 inhibitors, synthesis thereof, and intermediates theretoCELGENE CAR LLC·Filed 2021·Granted May 23, 2023·1 cites·10 claims
- 1284US10463672B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2017·Granted Nov 5, 2019·2 cites·13 claims
- 1383US9884062B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2017·Granted Feb 6, 2018·2 cites·34 claims
- 1481US11912644B2Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoateCELGENE CORP·Filed 2022·Granted Feb 27, 2024·0 cites·19 claims
- 1580US2022125797A1Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2022·Application pending·0 cites
- 1678US9975872B2Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereofCELGENE CORP·Filed 2016·Granted May 22, 2018·2 cites·12 claims
- 1774US11241439B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2020·Granted Feb 8, 2022·0 cites·12 claims
- 1874US9133161B2Processes for preparing isoindoline-1,3-dione compoundsCELGENE CORP·Filed 2013·Granted Sep 15, 2015·2 cites·11 claims
- 1972US10596180B2Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the sameCELGENE CORP·Filed 2019·Granted Mar 24, 2020·0 cites·14 claims
- 2072US2020316099A1Isotopologues of 5-azacytidineCELGENE CORP·Filed 2020·Application pending·0 cites
- 2171US9604939B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2014·Granted Mar 28, 2017·1 cites·10 claims
- 2269US11505522B2Processes for the preparation of (S)-tert-butyl 4,5- diamino-5-oxopentanoateCELGENE CORP·Filed 2020·Granted Nov 22, 2022·0 cites·20 claims
- 2369US10717703B2Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoateCELGENE CORP·Filed 2018·Granted Jul 21, 2020·0 cites·20 claims
- 2468US2015056280A1Isotopologues of 5-azacytidineCELGENE CORP·Filed 2014·Application pending·0 cites
- 2566US2023128975A1Process for the preparation of bromodomain inhibitorCELGENE QUANTICEL RES INC·Filed 2022·Application pending·0 cites
- 2664US9695145B2Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereofCELGENE CORP·Filed 2014·Granted Jul 4, 2017·0 cites·20 claims
- 2762US9969712B2Process for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·0 cites·24 claims
- 2859US9974786B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted May 22, 2018·0 cites·18 claims
- 2958US9795603B2Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their useSIGNAL PHARM LLC·Filed 2017·Granted Oct 24, 2017·0 cites·18 claims
- 3056US11566004B2Process for the preparation of bromodomain inhibitorCELGENE QUANTICEL RES INC·Filed 2019·Granted Jan 31, 2023·0 cites·17 claims
- 3155US11014940B1Thiazolidinone and oxazolidinone compounds and formulationsCELGENE CORP·Filed 2019·Granted May 25, 2021·0 cites·24 claims
- 3250US12227519B2Preparation of maytansinolCELGENE CORP·Filed 2020·Granted Feb 18, 2025·0 cites·11 claims
- 3349US2025346577A1Processes for the preparation of substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compoundsBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3449US2024246990A1Process of preparing (1r, 4r, 5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione(salinosporamide a; marizomib)CELGENE INT II SARL·Filed 2020·Application pending·0 cites
- 3548US2010063280A1Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compoundsSCHERING CORP·Filed 2007·Application pending·0 cites
- 3636US8680294B2Enantio- and stereo specific synthesis of β-amino-α-hydroxy amidesTRAVERSE JOHN·Filed 2010·Granted Mar 25, 2014·0 cites·7 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →